Bach Pharma, Inc. Is Dedicated To The Development Of New Therapeutics For The Treatment Of Life - Threatening Neurodegenerative Diseases.

Bach Pharma, Inc., a privately held company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life-threatening diseases. Bach’s lead program is targeting degenerative neurological illnesses with the goal to dramatically improve patients' lives and reduce the cost of global health care.

The company's lead candidate, GVT®, is a novel cytoprotective agent with promising powerful anti-oxidant and anti-inflammatory properties. GVT has the potential to treat serious diseases of the central nervous and immune systems, as many are associated with oxidative stress and inflammatory pathways.

 

Upcoming Events

Annual Meeting of Shareholders

April 21, 2017 (Friday)
3:00 PM – 4:00 PM

More event information...


Board of Directors Meeting

April 21, 2017 (Friday)
4:00 PM – 5:00 PM

April 22, 2017 (Saturday)
8:30 AM – 2:00 PM

More event information...

About Bach Pharma

Bach Pharma, Inc., (BACH), a privately held pharmaceutical company is a global leader in the development of revolutionary phthalazinedione-based therapeutics...

Science

Bach is dedicated to developing drugs that modulate fundamental pathways regulating redox status and oxidative injury, thus normalizing the cellular redox...

Clinical Programs

Bach Pharma is targeting serious and life threatening diseases in which oxidative stress plays a role. This includes neuroimmuno-degenerative illnesses...